Ascendis’ likely approval of TransCon CNP for achondroplasia poses a major threat to BioMarin’s best-selling drug. Read why I ...

Buying $1000 In ASND: If an investor had bought $1000 of ASND stock 10 years ago, it would be worth $8,301.91 today based on a price of $165.54 for ASND at the time of writing.

Ascendis Pharma A/S (Nasdaq: ASND) today announced new data from Week 156 of its Phase 3 PaTHway Trial confirming that long-term treatment with ...

“Ascendis is making important advances in its growing Endocrinology Rare Disease portfolio,” said Aimee Shu, M.D., Executive Vice President of Endocrine & Rare Disease Medical Sciences and ...

Ascendis Pharma (NASDAQ:ASND) A/S, a biopharmaceutical company focused on developing innovative therapies for rare endocrine disorders, has garnered significant attention from analysts due to its ...

Ascendis may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on ...

The average of price targets set by Wall Street analysts indicates a potential upside of 29.8% in Ascendis Pharma (ASND). While the effectiveness of this highly sought-after metric is questionable, ...

COPENHAGEN, Denmark, July 07, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced two oral presentations at ENDO 2025, the annual meeting of the Endocrine Society being held ...

In other recent news, Ascendis Pharma has been the subject of multiple analyst evaluations and updates. UBS maintained its buy rating and $197 price target for Ascendis Pharma, emphasizing the ...

Investing.com - UBS maintained its buy rating and $197.00 price target on Ascendis Pharma (NASDAQ:ASND) Wednesday, as the stock trades near its 52-week high of $183. The firm highlighted the ...

Ascendis Pharma A/S (ASND) key stats comparison: compare with other stocks by metrics: valuation, growth, profitability, momentum, EPS revisions, dividends, ratings.

Investing.com - UBS maintained its buy rating and $197.00 price target on Ascendis Pharma (NASDAQ: ASND) Wednesday, as the stock trades near its 52-week high of $183.